Abstract In the peripheral nervous system (PNS) in the absence of tight blood barrier, neurons are at increased risk of DNA damage, yet the question of how effectively PNS neurons manage DNA damage remains largely unanswered. Genotoxins in systemic circulation include chemotherapeutic drugs that reach peripheral neurons and damage their DNA. Because neurotoxicity of platinum-based class of chemotherapeutic drugs has been implicated in PNS neuropathies, we utilized an in vitro model of Dorsal Root Ganglia (DRGs) to investigate how peripheral neurons respond to cisplatin that forms intra-and interstrand crosslinks with their DNA. Our data revealed strong transcriptional upregulation of the translesion synthesis DNA polymerase kappa (Pol κ), while expression of other DNA polymerases remained unchanged. DNA Pol κ is involved in bypass synthesis of diverse DNA lesions and considered a vital player in cellular survival under injurious conditions. To assess the impact of Pol κ deficiency on cisplatin-exposed DRG neurons, Pol κ levels were reduced using siRNA. Pol κ targeting siRNA diminished the cisplatin-induced nuclear Pol κ immunoreactivity in DRG neurons and decreased the extent of cisplatin-induced DNA repair synthesis, as reflected in reduced incorporation of thymidine analog into nuclear DNA. Moreover, Pol κ depletion exacerbated global transcriptional suppression induced by cisplatin in DRG neurons. Collectively, these findings provide the first evidence for critical role of Pol κ in DNA damage response in the nervous system and call attention to implications of polymorphisms that modify Pol κ activity, on maintenance of genomic integrity and neuronal function in exogenously challenged PNS.
Introduction
Circulating chemotherapeutic drugs readily reach neurons of the peripheral nervous system (PNS), and their neurotoxicity hinders attainment of chemotherapy goals [1] . Salient example of a chemotherapeutic agent associated with peripheral neurotoxicity is cisplatin, a drug commonly used in treatment of solid tumors [2, 3] . Cisplatin belongs to the class of platinum-based drugs that form bulky adducts, primarily intra-and interstrand DNA crosslinks [4] . Although bulky adducts hinder critical DNA transaction and have miscoding Ming Zhuo and Murat F. Gorgun are the co-first authors Electronic supplementary material The online version of this article (doi:10.1007/s12035-017-0507-5) contains supplementary material, which is available to authorized users.
potential, the scope of their repair in the nervous system has not been elucidated. To gain insight into neuronal DNA damage response and cisplatin crosslinks repair in the PNS, we used an in vitro model of dorsal root ganglion (DRG) neurons challenged with cisplatin. Our study reveals that in DRG neurons, cisplatin and other genotoxic agents including, doxorubicin and cytarabine, strongly induce expression of the Y-family, translesion synthesis (TLS) DNA polymerase kappa (Pol κ), while transcription of other DNA polymerases remains unchanged.
TLS polymerases catalyze bypass synthesis of diverse DNA lesions and, while considered vital players in cellular survival under injurious conditions, may also promote mutagenesis [5] [6] [7] [8] [9] . Although some studies showed that elevated Pol κ promotes genomic instability [5] , other studies showed that Pol κ protects cells from mutagens [10, 11] and that Pol κ deficiency may exacerbate mutagenesis [12, 13] . Interestingly, studies also demonstrated that Pol κ participates in processing of different types of oxidative lesions, including strand breaks [14] , bypass of 8-oxo-dG [15] and abasic sites [8, 16] , which are base excision repair (BER) substrates, as well as processing of bulky lesions that are substrates of the nucleotide excision repair (NER) pathway [17, 18] . This suggests that in neurons, Pol κ might have a role in repair of diverse lesions, including cisplatin/DNA crosslinks, which are typical NER substrates [19] , and in fact, cells lacking Pol κ are partially defective in interstrand crosslink removal [20, 21] . Interestingly, unlike other TLS polymerases, Pol κ rarely localizes to replication forks [22] , its levels are highest in the G0 phase of cell cycle, and its affinity for dNTPs is higher compared to other DNA polymerases [17] . Taken together, these features are consistent with preference for nondividing cells [18, 23] supporting a role for Pol κ in replication-independent DNA repair, prerequisite in the terminally differentiated neurons. Indeed, region-specific analyses of Pol κ mRNA in the mouse brain [24] revealed constitutive expression levels second only to BER polymerase beta (Pol β), which is the major DNA polymerase in the nervous system [24, 25] . Notwithstanding, to date, the physiological role of Pol κ in the nervous system has not been elucidated. Here, we report marked upregulation of Pol κ expression in cultured dorsal root ganglion neurons in response to different genotoxic insults, while levels of other DNA polymerases remain unchanged under similar conditions. Moreover, we observe increasing immunoreactivity of nuclear Pol κ protein in the course of cisplatin exposure of DRG neurons and reduced postcisplatin DNA repair synthesis when Pol κ levels are depleted. Collectively, our data suggest that Pol κ might have a central role in DNA damage response and neuronal survival in the face of endogenous and exogenous insults that challenge DNA integrity in neurons.
Methods

Culture of Mouse Dorsal Root Ganglion Neurons
Mouse-handling procedures were approved by Institutional Animal Care and Use Committee of the University of Texas Medical Branch. Dorsal root ganglion neurons were isolated from male C57BL/6 mice 3-4 months old (Harlan Laboratories, USA) as described [26] [27] [28] [29] [30] . Ganglia dissected from all spinal levels were placed in cold solution (130 mM NaCl, 5 mM KCl, 2 mM KH 2 PO 4 , 1.5 mM CaCl 2 , 6 mM MgCl 2 , 10 mM glucose, and 10 mM Hepes, pH 7.2), incubated (1 h/37°C) with collagenase A (Roche) and trypsin followed by DNase I (Roche), dissociated by 20 slow triturations and spun (168 g/3 min). Pellets were passed through 70 μm strainer, spun and re-suspended in DMEM/F12 (Sigma) with 10% FBS, 10 ng/ml nerve growth factor (Sigma), and supplemented with penicillin/streptomycin. Cells were seeded at (3-5)×10 3 /cm 2 on precoated (10 μg/ml laminin and 100 μg/ml poly-L-ornithine) glass coverslips or plate wells. Treatments were initiated 24 h after seeding. The low sublethal 10 μM dose of cisplatin (Cis-Diammineplatinum (II) dichloride Sigma P4394) was selected to initiate the DNA damage response without causing significant neuronal death; cisplatin dose-linked cell death was previously determined by MTT assay and trypan blue uptake [31] . The dose agrees with earlier reports on cisplatin dosage and DRG neurons viability [32] .
Delivery of siRNA
To reduce Pol κ levels in DRG neurons, small interfering RNA (siRNA) was applied using the Accell system (Dharmacon Inc.) designed to optimize transfection of primary cells. At 24 h after seeding, siRNA was added at final concentration of 1 μM in Accell siRNA delivery medium (Dharmacon, #B-005000) and incubated for 12 h prior to the addition of 2% FBS for the duration of subsequent treatments. Transfection efficiency was assessed by imaging internalized nontargeting red fluorescent siRNA (#D-001960-01, Dharmacon) in cultures of DRG neurons and determined to be nearly 70% (supplementary Fig. 1 ). Transfections were either with nontargeting siRNA (#D-001910-05, Dhar maco n) or Pol κ targ eting siRNA mixture (#A-048146-13 and #A-048146-14 Dharmacon).
Real-Time Quantitative PCR
Total RNA was isolated from cultured DRG neurons (4 × 10 4 / 3.5-cm dish) using RNeasy plus mini kit (Qiagen) and reverse transcribed with iScript RT supermix (Bio-Rad), which contains random and oligo dT primers. Real-time PCR was done with CFX96 Real-Time System (Bio-Rad) as we described [30, 31] . 18S and B2M gene transcripts were used as internal controls. PCR reactions were assembled in duplicates with SSO FAST Evagreen supermix (Bio-Rad). PCR program was 95°C 2 min, 40 cycles of 95°C 5 s, and 55°C 15 s. Data represent averages of at least three sets of independent biological experiments. The relative amount of target gene RNA was calculated as described [33] using the formula:
Primer sequences are given in Supplementary Table 1.
Immunofluorescent Staining
DRG neurons were seeded on pre-coated coverslips in 24-well plates and processed as we described [30, 31] . Briefly, coverslips were washed 2× with PBS, fixed in 4% paraformaldehyde, rinsed, permeabilized with 0.1% Triton X-100/0.1% sodium citrate in PBS (9 min), and blocked in PBS with 3% BSA (w/v)/1% Donkey serum (v/v) for 40 min/37°C. Primary antibodies were rabbit anti-Neurofilament 200 (1:20,000, Sigma-N4142), mouse anti Pol κ (1:12,000, Sigma-WH0051426M), and mouse anti γH 2 AX (1:4000, Millipore #05-636). Coverslips were washed 3× in 1% BSA in PBS, incubated 45 min in the dark with 488 and 594 Alexa-dye conjugated anti-mouse and anti-rabbit IgG (Life Technologies). Coverslips were mounted with Prolong® Gold Anti-fade with DAPI (Life Technologies) and viewed/ captured with 40× objective using Olympus IX71 fitted with QIC-F-M-12-C cooled camera (QImaging, Surrey, BC) and QCapture Pro (QImaging) software. Fluorescence intensity was quantified using ImageJ (National Institutes of Health) software.
EdU Incorporation
DNA repair synthesis was monitored by incorporation of EdU i n t o n e w l y s y n t h e s i z e d D N A [ 3 4 , 3 5 ] . E d U (5-ethynyl-2′-deoxyuridine), a nucleoside analog of thymidine, was detected via the Click-iT R reaction generated fluorescence (EdU Imaging kit #C10339, Invitrogen). Of note, DNA repair synthesis, referred to as unscheduled DNA synthesis, generates very weak signal compared to strong fluorescence produced by EdU incorporation during S phase replication synthesis. To accurately quantify EdU incorporation during repair synthesis, background fluorescence measured in cells subjected to the Click-iT reaction when EdU is omitted was subtracted from readings to set up cutoff for EdU positivity. To measure incorporation, control and cisplatin-exposed DRG neurons were supplemented with 10 μM EdU for the duration of treatments. Readily measurable EdU signal was generated following 24 h cisplatin exposure, with no positive signal in nonexposed DRG neurons. After treatment, cells were fixed with 4% paraformaldehyde for 20 min, washed in PBS, permeabilized with 0.1% Triton X-100/0.1% sodium citrate (Sigma) for 9 min, and rinsed with PBS. EdU detecting mix (Kit #C10339) with Alexa Fluor dye 594 was applied at 1:1000 dilution and incubated for 30 min at 25°C protected from light. Coverslips were washed with PBS and processed for immunofluorescent staining with anti Pol κ antibody as described above. EdU fluorescence was observed under Olympus IX71 microscope; images were captured with QIC-F-M-12-C cooled digital camera, and nuclear fluorescence was quantified and normalized to nuclear area using the ImageJ software (NIH). Three sets of independent biological experiments were done, and at least 50 DRG neurons were quantified from randomly selected fields for each experimental condition.
EU Incorporation
Global RNA synthesis was assessed by imaging incorporation of EU (5-ethynyl uridine), an alkyne-modified uridine analog, into newly synthesized RNA transcripts. Incorporated EU was detected via Click-IT R reaction as previously described [34] [35] [36] . Briefly, 60 min before termination of treatments, DRGs cultures were supplemented with 0.5 mM EU. Cultures were fixed with 4% paraformaldehyde, protected from light and processed according to manufacturer with Click-iT® RNA Alexa Fluor® 594 Imaging Kit (Kit #C10330, Invitrogen). Coverslips were then reacted with anti Pol κ antibody to concomitantly monitor Pol κ levels. Coverslips were observed with Olympus IX71 microscope; images were captured with QIC-F-M-12-C cooled digital camera, and mean nuclear intensity was determined using ImageJ software (NIH). Three biological experiments were done, and fluorescence of ≥50 DRG neurons from randomly captured fields was quantified for each experimental condition. Mean fluorescence intensity of individual nuclei was calculated and frequency histograms generated.
Statistical Analysis
Data are given as mean ± SEM obtained from three to four independent biological experiments, as indicated. One-way ANOVA was employed to compare the means among groups followed by posttest Tukey's analysis to determine differences in means of multiple groups or as indicated. P < 0.05 was considered statistically significant. MegaStat® package for Excel was used.
Results
Genotoxins Upregulate DNA Pol κ Expression in DRG Neurons DNA Pol κ mRNA expression pattern in the mouse brain was previously analyzed by in situ hybridization (ISH), and the data are available from Allen Brain Atlas [24] . Compared to expression of other DNA polymerases, baseline level of Pol κ mRNA in the mouse brain is second only to that of DNA polymerase beta (Pol β) (Fig. 1a) , the major DNA polymerase in the nervous system [25] . To asses Pol κ baseline mRNA levels in the central and peripheral nervous system, we carried out real-time (RT) qPCR analyses of RNA from cultured cortical and DRG neurons. Relative levels of Pol κ mRNA were calculated versus 18S (left) and versus Pol β (right), which is highly expressed in the nervous system [24] . Analyses revealed ∼3.5-fold higher expression of Pol κ in DRG when compared to cortical neurons (Fig. 1b) ; relative to Pol β, Pol κ mRNA levels were ∼35 and ∼10% in DRG and cortical neurons, respectively. Similar ratios of Pol κ expression were measured also when using 18S mRNA as reference (Fig. 1b,  left) .
To assess Pol κ inducibility at transcriptional level, cultured DRG neurons were exposed to the DNA damaging agents cisplatin, doxorubicin, and cytarabine (ara-C) that produce different types of DNA damage. Cisplatin forms intra-and interstrand crosslinks with DNA [4] , doxorubicin inhibits topoisomerase ll [37] , and ara-C is an antimetabolite that blocks DNA synthesis [38] . RT-qPCR analyses revealed that in DRG neurons, genotoxins upregulate Pol κ transcription 3-4-fold, while the expression of other DNA polymerases remains unchanged (Fig. 1c) . Because cisplatin is implicated in peripheral neurotoxicity, we examined temporal transcription patterns of DNA repair proteins in the course of cisplatin exposures (Fig. 2) . RT-qPCR analyses after 2, 4, 8, 16, 24, or 48 h exposure to cisplatin (10 μM) revealed elevated expression of Pol κ by 8 h with further increases at 16 and 24 h and return to normal by 48 h. In contrast, RNA levels of the other Y-family TLS polymerases (Pol η, Pol ι, and Rev1), X family Pol β and Pol λ, and B family Pol δ and mitochondrial Pol γ remained unchanged. In addition to Pol κ, among 14 genes encoding proteins involved in DNA repair, only expression of the gene encoding Xeroderma Pigmentosum complementation group A (Xpa) protein was also upregulated. Xpa is a zinc finger protein [39] involved in damage sensing/ verification and recruitment of repair proteins to sites of damage; transcriptional regulation of Xpa protein has been reported previously [40] .
Cisplatin Exposures Induce γH 2 AX Foci and Nuclear Pol κ Immunoreactivity in DRG Neurons
Next, we asked whether exposure to sublethal dose of cisplatin, which upregulates Pol κ transcription, might also initiate the DNA damage response and upregulate Pol κ protein levels in DRG neurons. Continuous exposure to 10 μM cisplatin led to formation of γH 2 AX foci, which first appeared by 4 h and temporally increased in density and intensity in the course of treatment (Fig. 3a) . Nuclear γH 2 AX foci are considered markers of chromatin rearrangements mediated by phosphorylation of H 2 AX variant histone at serine 139, which facilitate accessibility of repair proteins and execution of DNA damage repair [41, 42] . Induction of strong nuclear Pol κ immunoreactivity was also observed in the course of cisplatin exposure (Fig. 3b) , albeit temporally lagging behind formation of γH 2 AX foci. Baseline immunoreactivity of Pol κ, which in nonchallenged DRG nuclei ranged from undetectable to weak, increased markedly in the course of 24 h cisplatin 
Cisplatin-Induced DNA Repair Synthesis Is Diminished by siRNA-Mediated Knockdown of Pol κ Expression in DRG Neurons
Cisplatin triggers formation of DNA crosslinks that are resolved primarily via the NER pathway. Following excision, NER process involves a critical step of gap filling DNA synthesis. Pol κ has been implicated in catalyzing this step in different models of DNA damage [17, 18, 43] . To assess the extent of cisplatin-induced DNA repair synthesis in a system of terminally differentiated cells, DRG cultures were supplemented with EdU at the time of cisplatin addition. EdU is an alkyne-modified thymidine analog, whose incorporation into DNA is detectable in situ via fluorescence generated using Click-iT chemistry [34, 35] routine maintenance DNA repair synthesis in nonchallenged DRG neurons did not generate fluorescence above background levels (left), whereas cisplatin exposure induced a readily measurable nuclear EdU signal that coincided with cisplatin-induced Pol κ immunoreactivity (Fig. 4a, center) .
To assess to what extent Pol κ deficiency might affect DNA repair synthesis in cisplatin-exposed DRG neurons, Pol κ expression was reduced using small interfering RNA (PolK-siRNA). Depletion of Pol κ protein is expected within the time frame of our experimental setting since the reported Pol κ half-life is approximately 5.4 h [44] . The Accell siRNA system designed to maximize transfection efficiency of primary cells was used. At 24 h postseeding (when neurite network is established), DRG cultures were supplemented with either random/nontargeting (nt-siRNA) or Pol κ targeting (PolK-siRNA) siRNA and incubated for 12 h prior to the addition of cisplatin and for the subsequent 24 h duration of treatment. PolK-siRNA transfection led to partial reduction of cisplatin-induced Pol κ immunoreactivity in nearly 50% of DRG neurons, concordant with expectations based on the nearly 70% siRNA transfection efficiency observed for DRG neurons. Importantly, cisplatin-induced nuclear fluorescence of incorporated EdU was reduced when Pol κ was depleted by siRNA (right, arrowhead). Following treatments, mean EdU fluorescence was calculated for the individual DRG nuclei. Frequency histograms revealed reduction in cisplatin-induced EdU incorporation in DRG cultures transfected with PolK-siRNA compared to nt-siRNA (Fig. 4b) . Scatter plots of fluorescent signals recorded for the individual nuclei of DRG neurons exposed to cisplatin in the presence of nt-siRNA (green dots) or PolK-siRNA (black diamonds) show positive correlation between levels of Pol κ immunoreactivity and EdU fluorescence (Fig. 4c) .
Cisplatin-Induced Suppression of RNA Synthesis in DRG Neurons Is Exacerbated by Pol κ Depletion
Global RNA synthesis was assessed by incorporation of EU (5-ethynyl uridine), an alkyne-modified uridine analog, into newly synthesized nascent RNA. DRG cultures were incubated with 0.5 mM EU for 60 min prior to termination of treatments to measure EU incorporation into the newly synthesized RNA. Incorporated EU was visualized by Click iT chemistry (Fig. 5a, red) ; detection of EU by Click-iT R chemistry was previously described [34, 35] . Strong EU fluorescence with intense nucleolar signal was observed in control cultures (Fig. 5a, left by cisplatin. EU intensity was further reduced in DRG cultures supplemented with PolK-siRNA during cisplatin exposure (right, red). Concomitant assessment of Pol κ immunofluorescence revealed diminution by PolK-siRNA of the cisplatin-induced nuclear Pol κ immunoreactivity. EU intensity in individual nuclei was quantified using ImageJ, and resultant frequency histograms revealed marked reduction of EU intensity by cisplatin, with a trend for further diminution by Pol κ knockdown (Fig. 5b) . The average EU intensity in DRG nuclei was reduced by 47% by 10 μM cisplatin and by additional 14% when DRG neurons were supplemented with PolK-siRNA during cisplatin exposure (Fig. 5c ). Scatter plots (Fig. 5d ) of individual nuclei of control neurons (red triangles) and of neurons exposed to cisplatin revealed substantial reduction of EU incorporation into newly synthesized RNA (green dots). Suppression of EU incorporation by cisplatin was further exacerbated by transfection of PolK-siRNA, which led to diminution of the cisplatin-induced nuclear Pol κ immunofluorescence (black diamonds).
Discussion
Neuronal DNA repair pathways that process the different types of DNA damage have not been fully deciphered. This is a particular concern in the peripheral nervous system [45] where in the absence of tight blood barrier, neurons are poorly shielded from circulating genotoxins, including chemotherapeutic drugs. An example of a drug that presents significant problems in the clinic is cisplatin whose neurotoxicity and associated peripheral neuropathies hinder cancer care. Here, using an in vitro system of dorsal root ganglion (DRG) neurons, we show that cisplatin exposures initiate the DNA damage response, upregulate expression of TLS DNA polymerase kappa (Pol κ), and suppress global RNA synthesis. Pol κ belongs to the Y-family of error-prone TLS polymerases that are implicated in bypass of various DNA lesions [46] . While similarly to other TLS DNA polymerases, Pol κ is subject for tight transcriptional and posttranslational controls [46, 47] , Pol κ is considered less error prone and its levels are not kept as low as levels of other TLS polymerases [48] [49] [50] . In fact, reports show that Pol κ catalyzes accurate bypass of multiple DNA lesions [10, 11, 51, 52] , accurate extension beyond the benzo[a]pyrene bulky adduct [53] , accurate synthesis on dinucleotide microsatellite DNA [54] and on non-B DNA structures [55] , and error-free synthesis on nondamaged DNA templates suggesting that Pol κ upregulation could be advantageous without significantly increasing mutagenesis and in some cases even promote genomic stability [56] . While Pol κ can bypass multiple types of DNA lesions, including bulky adducts, due to the structure of its active site, it poorly inserts bases opposite pyrimidine dimers [57] , which might be consistent with a more central role in the nervous system that is mostly sheltered from UV light. Furthermore, unlike other TLS polymerases, Pol κ rarely localizes to replication forks [22] and does not absolutely depend on PCNA interactions [58] . In proliferating cells, Pol κ levels are highest in the G0 phase of cell cycle and its affinity for dNTPs is higher compared to other polymerases [17] . Intriguingly, PolK−/− cells are more sensitive to cisplatin treatment in the non-S phase of cell cycle supporting a specialized role for Pol κ in the replication-independent DNA repair process [21] that is critical in terminally differentiated cells. When considered together, these features that are consistent with a preference for nondividing cells [18, 23] are suggestive of more prominent role for Pol κ in neuronal DNA repair. The fact that Pol κ is involved in handling diverse DNA lesions and indeed in DRG neurons we detect significant induction of Pol κ in response to diverse genotoxic insults, while levels of other TLS polymerases remain unchanged, supports this notion. Pol κ involvement in resolution of DNA lesions includes the gap-filling step of NER [17] and clearance of cisplatin crosslinks [43, 59] . We found that in DRG neurons, Pol κ transcription is significantly upregulated by cisplatin, while expression of other TLS polymerases remains unchanged. Similarly, mRNA levels of genes encoding DNA repair proteins involved in different repair pathways remain unchanged under these conditions, with the exception of Xeroderma Pigmentosum complementation group A (Xpa) gene. Xpa is a zinc finger protein central in damage sensing, verification [39] and recruitment of proteins that participate in both global and transcription coupled NER processes [60] . Transcriptional control of Xpa [40, 61] , its binding to DNA distorting cisplatin adducts [62, 63] , and its involvement in resolution of cisplatin crosslinks [20] have been reported. Since Xpa has been implicated in resolution of cisplatin crosslinks and in view of our findings, it is plausible that in DRG neurons, Xpa participates in NER processes that involve Pol κ catalyzed gap filling DNA synthesis.
To gain new insight into the process of cisplatin adducts clearance in DRG neurons, the gap-filling step of NER was examined by monitoring incorporation of EdU (thymidine analog) as surrogate for gap-filling DNA repair synthesis. We found that in DRG neurons, cisplatin induces DNA repair synthesis reflected in measurable incorporation of EdU. As expected, in the nonchallenged DRG neurons, EdU incorporation during routine maintenance repair synthesis is below detection limit. EdU incorporation in the course of continuous cisplatin exposure is readily detectable, plausibly because the NER process involves 30 nucleotide-long stretches of gap filling DNA synthesis [64] and high frequency of cisplatin adducts was observed following cisplatin exposures [65] . Importantly, here, EdU incorporation positively correlated with cisplatin-induced elevation of Pol κ immunoreactivity in DRG nuclei, whereas siRNA-mediated depletion of Pol κ was associated with reduced incorporation of EdU into genomic DNA, suggesting that Pol κ is involved in gap-filling DNA repair synthesis in cisplatin-exposed DRG neurons.
In view of evidence supporting the involvement of Pol κ in response to cisplatin challenge in DRG neurons, we also asked whether Pol κ deficiency might exacerbate cisplatin-induced transcriptional suppression. To this end, we measured incorporation of EU (uridine analog) into newly synthesized nascent RNA. Consistently with earlier reports [65] [66] [67] , we found that cisplatin causes major suppression of the inherently robust global RNA synthesis in DRG neurons, plausibly reflecting formation of transcription-blocking cisplatin adducts. Importantly, we found that in DRG neurons, transcriptional suppression by cisplatin was modestly exacerbated by siRNA-mediated Pol κ knockdown, suggesting that Pol κ contributes to resolution of cisplatin adducts and thereby helps relieve the cisplatin-induced blockade of RNA synthesis.
Collectively, our findings indicate that in DRG neurons, depletion of Pol κ slows the gap filling DNA synthesis step in the NER process, causing a delay in clearance of cisplatin adducts and thereby a delay in resumption of RNA synthesis. Hence, Pol κ might have a critical role in neuronal DNA damage repair and preservation of neuronal function, whereas Pol κ deficiency can sensitize DRG neurons to genotoxic insults. Because basal levels of Pol κ are higher in DRG compared to cortical neurons, it is plausible that in DRG neurons, which are not protected by a tight blood barrier [68, 69] , Pol κ affords greater capacity for coping with DNA damage [45] . Although speculative, this distinction highlights the possibility that DNA repair mechanisms necessitated by different levels of shielding may differ within the nervous system, and the less protected PNS neurons might have adapted to acquire more robust repair capacity. Together, the data provide new insights into neuronal DNA damage response and suggest that Pol κ might have a vital role in neuronal DNA damage repair.
